Skip to content

Feed Screener Search Methodology

SEC · FI · BAFIN · AFM · AMF

Pricing Sign in

InsiderLens

Statistics predict. AI explains.

Insider transactions from public regulatory disclosures, aggregated and enriched with deterministic statistical signals. Not investment advice.

Sources

SEC EDGAR · US
FINANSINSPEKTIONEN · SE
BAFIN · DE
AFM · NL
AMF · FR

Product

Methodology
Privacy notice
Object to processing

Feed Screener Search Methodology

Pricing Sign in

Kuvalanka Kyle D. — Syros Pharmaceuticals, Inc. insider: 1 transactions · InsiderLens

Home / Insiders / Kuvalanka Kyle D.

Kuvalanka Kyle D.

Chief Financial Officer at Aktis Oncology, Inc. · on record since Jan 8, 2026
Chief Business Officer at Blueprint Medicines Corp · on record since Apr 30, 2015
Chief Operating Officer at Syros Pharmaceuticals, Inc. · on record since Jun 29, 2016

Insider trading activity of Kuvalanka Kyle D.

Transactions on record: 1; since Feb 13, 2017

Open-market buys: 0

Open-market sells: 0

Companies traded: 1; last filing Feb 13, 2017

Figures computed from official regulatory filings — methodology.

Companies where Kuvalanka Kyle D. has traded

Syros Pharmaceuticals, Inc.1 tx · Feb 13, 2017

Track record of Kuvalanka Kyle D.

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of Kuvalanka Kyle D.

Co-insiders of Kuvalanka Kyle D.

AFEYAN NOUBARSyros Pharmaceuticals, Inc.
Aichele DavidAktis Oncology, Inc.
AISLING CAPITAL III LPSyros Pharmaceuticals, Inc.
Aisling Capital Partners III LLCSyros Pharmaceuticals, Inc.
Aisling Capital Partners III LPSyros Pharmaceuticals, Inc.
AKKARAJU SRINIVASSyros Pharmaceuticals, Inc.
Albers Jeffrey W.Blueprint Medicines Corp

This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →

Alles Mark JSyros Pharmaceuticals, Inc.

Arch Venture Fund VII LPSyros Pharmaceuticals, Inc.

ARCH Venture Partners VII, LLCSyros Pharmaceuticals, Inc.

ARCH Venture Partners VII, L.P.Syros Pharmaceuticals, Inc.

Bancel StephaneSyros Pharmaceuticals, Inc.

Beckman DaniellaBlueprint Medicines Corp

Boller KennethAktis Oncology, Inc.

BONNEY MICHAEL WSyros Pharmaceuticals, Inc.

Boomgarden MarkAktis Oncology, Inc.

Boral Anthony L.Blueprint Medicines Corp

Borisy AlexisBlueprint Medicines Corp

BYBEE CLINTONSyros Pharmaceuticals, Inc.

Carter Percy H.Blueprint Medicines Corp

Chee ConleySyros Pharmaceuticals, Inc.

Cheema KamranAktis Oncology, Inc.

COATS LONNELBlueprint Medicines Corp

Conde JorgeSyros Pharmaceuticals, Inc.

CRANDELL KEITHSyros Pharmaceuticals, Inc.

Czibere AkosAktis Oncology, Inc.

Dable Habib JBlueprint Medicines Corp

Demetri GeorgeBlueprint Medicines Corp

Denbaars StevenAktis Oncology, Inc.

DeSimone Colleen ElizabethSyros Pharmaceuticals, Inc.

Dorsch MarionBlueprint Medicines Corp

Dunsire DeborahSyros Pharmaceuticals, Inc.

Durso-Bumpus DebraBlueprint Medicines Corp

Eckhardt Sue GailSyros Pharmaceuticals, Inc.

EcoR1 Capital, LLCAktis Oncology, Inc.

ELMS STEVESyros Pharmaceuticals, Inc.

EVNIN LUKEAktis Oncology, Inc.

Fanucci MarshaSyros Pharmaceuticals, Inc.

Feldman Paul LAktis Oncology, Inc.

Ferra Joseph J JrSyros Pharmaceuticals, Inc.

Flagship VentureLabs IV, LLCSyros Pharmaceuticals, Inc.

Flagship Ventures Fund IV General Partner LLCSyros Pharmaceuticals, Inc.

Flagship Ventures Fund IV, L.P.Syros Pharmaceuticals, Inc.

Flagship Ventures Fund IV-Rx, L.P.Syros Pharmaceuticals, Inc.

FMR LLCBlueprint Medicines Corp

Foley ToddAktis Oncology, Inc.

Frizzley Jill KathleenAktis Oncology, Inc.

GADICKE ANSBERTAktis Oncology, Inc.

Geiss ArthurAktis Oncology, Inc.

Goldberg Mark AlanBlueprint Medicines Corp

Company	Filed	Type	Qty	Price	Value · USD	Src
Syros Pharmaceuticals, Inc.	Feb 13, 2017	AwardD	78,000	0.00 USD	$0	SEC